https://www.selleckchem.com/products/ml390.html
Despite three decades of research to its name and increasing interest in immunotherapies that target it, LAG-3 remains an elusive co-inhibitory receptor in comparison to the well-established PD-1 and CTLA-4. As such, LAG-3 targeting therapies have yet to achieve the clinical success of therapies targeting other checkpoints. This could, in part, be attributed to the many unanswered questions that remain regarding LAG-3 biology. Of these, we address (i) the function of the many LAG-3-ligand interactions, (ii) the hurdles that remain to acqu
Like
Comment
Share
